Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder

Journal of Clinical Psychopharmacology

Volumn 30, Issue 3, 2010, Pages 294-299

  Kornstein, Susan G ^a   Clayton, Anita H ^b   Soares, Claudio N ^c   Padmanabhan, Sudharshan K ^d   Guico Pabia, Christine J ^d  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d PFIZER INC   (United States)

Author keywords

Age; Desvenlafaxine; Major depressive disorder; Sex; SNRI

Indexed keywords

DESVENLAFAXINE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HAMILTON SCALE; HUMAN; HYPERHIDROSIS; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; SEX DIFFERENCE; SOMNOLENCE; TREMOR; VOMITING; XEROSTOMIA;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AMBULATORY CARE; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEX FACTORS; STATISTICS AS TOPIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952371046     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181dcb594     Document Type: Article

References (31)

1. Kessler RC, McGonagle KA, Swartz M, et al. Sex and depression in the National Comorbidity Survey: I. Lifetime prevalence, chronicity and recurrence. J Affect Disord. 1993;29:85-96.
2. Young EA, Kornstein SG, Marcus SM, et al. Sex differences in response to citalopram: a STAR*D report. J Psychiatr Res. 2009;43: 503-511.
3. Marcus SM, Kerber KB, Rush AJ, et al. Sex differences in depression symptoms in treatment-seeking adults: confirmatory analyses from the Sequenced Treatment Alternatives to Relieve Depression study. Compr Psychiatry. 2008;49:238-246.
4. Grigoriadis S, Robinson GE. Gender issues in depression. Ann Clin Psychiatry. 2007;19:247-255.
5. McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocr Rev. 1999;20:279-307.
6. Rubinow DR, Schmidt PJ, Roca CA. Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatry. 1998;44:839-850.
7. Kendall DA, Stancel GM, Enna SJ. The influence of sex hormones on antidepressant-induced alterations in neurotransmitter receptor binding. J Neurosci. 1982;2:354-360.
8. Klaiber EL, Broverman DM, Vogel W, et al. Relationships of serum estradiol levels, menopausal duration, and mood during hormonal replacement therapy. Psychoneuroendocrinology. 1997;22:549-558.
9. Hendrie HC, Callahan CM, Levitt EE, et al. Prevalence rates of major depressive disorders: the effects of varying the diagnostic criteria in an older primary care population. Am J Geriatr Psychiatry. 1995;3:119-131.
10. Koenig HG, Cohen HJ, Blazer DG, et al. Profile of depressive symptoms in younger and older medical inpatients with major depression. J Am Geriatr Soc. 1993;41:1169-1176.
11. Husain MM, Rush AJ, Sackeim HA, et al. Age-related characteristics of depression: a preliminary STAR*D report. Am J Geriatr Psychiatry. 2005;13:852-860.
12. Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry. 2001;62:869-877.
13. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry. 2000;157:1445-1452.
14. Kornstein SG, Wohlreich MM, Mallinckrodt CH, et al. Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials. J Clin Psychiatry. 2006;67:761-770.
15. Thase ME, Entsuah R, Cantillon M, et al. Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. J Womens Health (Larchmt). 2005;14:609-616.
16. Baca E, Garcia-Garcia M, Porras-Chavarino A. Gender differences in treatment response to sertraline versus imipramine in patients with nonmelancholic depressive disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:57-65.
17. Papakostas GI, Kornstein SG, Clayton AH, et al. Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender-age interactions. Int Clin Psychopharmacol. 2007;22:226-229.
18. Pinto-Meza A, Usall J, Serrano-Blanco A, et al. Gender differences in response to antidepressant treatment prescribed in primary care. Does menopause make a difference? J Affect Disord. 2006;93:53-60.
19. Boyer P, Montgomery S, Lepola U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol. 2008;23:243-253.
20. DeMartinis NA, Yeung PP, Entsuah R, et al. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007;68:677-688. (Pubitemid 46841850)
21. Liebowitz M, Manley AL, Padmanabhan SK, et al. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/d and 100 mg/d in outpatients with major depressive disorder. Curr Med Res Opin. 2008;24:1877-1890.
22. Septien-Velez L, Pitrosky B, Padmanabhan SK, et al. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2007;22:338-347.
23. Thase ME, Kornstein SG, Germain J-M, et al. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr. 2009;14:144-154.
24. Liebowitz M, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry. 2007; 68:1663-1672. (Pubitemid 350247495)
25. Lieberman DZ, Montgomery SA, Tourian KA, et al. A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol. 2008;23: 188-197.
26. Feiger AD, Tourian K, Rosas G, et al. A placebo-controlled efficacy and safety study of a flexible dose of desvenlafaxine in outpatients with major depressive disorder. CNS Spectr. 2009;14:41-50.
27. Hamilton M. Hamilton Rating Scale for Depression (Ham-D). In: Rush AJ, Pincus HA, First MB, et al, eds. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000:526-529.
28. Montgomery SA, A° sberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
29. Guy W, ed. Clinical Global Impressions. Publication ADM 76-338. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare; 1976:217-222.
30. Bech P. Psychometric developments of the Hamilton scales: the spectrum of depression, dysthymia, and anxiety. In: Bech P, Coppen A, eds. The Hamilton Scales. Berlin: Springer-Verlag; 1990:72-79.
31. Clayton AH, Kornstein SG, Rosas G, et al. An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr. 2009;14: 183-195.